JP2010502207A5 - - Google Patents

Download PDF

Info

Publication number
JP2010502207A5
JP2010502207A5 JP2009527144A JP2009527144A JP2010502207A5 JP 2010502207 A5 JP2010502207 A5 JP 2010502207A5 JP 2009527144 A JP2009527144 A JP 2009527144A JP 2009527144 A JP2009527144 A JP 2009527144A JP 2010502207 A5 JP2010502207 A5 JP 2010502207A5
Authority
JP
Japan
Prior art keywords
seq
region
binding molecule
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009527144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010502207A (ja
JP5161882B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/059356 external-priority patent/WO2008028946A2/en
Publication of JP2010502207A publication Critical patent/JP2010502207A/ja
Publication of JP2010502207A5 publication Critical patent/JP2010502207A5/ja
Application granted granted Critical
Publication of JP5161882B2 publication Critical patent/JP5161882B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009527144A 2006-09-07 2007-09-06 インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用 Active JP5161882B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US84293006P 2006-09-07 2006-09-07
US60/842,930 2006-09-07
EP06120316 2006-09-07
EP06120316.2 2006-09-07
EP06120644 2006-09-14
EP06120644.7 2006-09-14
EP06125107 2006-11-30
EP06125107.0 2006-11-30
EP07111235.3 2007-06-28
EP07111235 2007-06-28
PCT/EP2007/059356 WO2008028946A2 (en) 2006-09-07 2007-09-06 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012179593A Division JP5701827B2 (ja) 2006-09-07 2012-08-13 インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用

Publications (3)

Publication Number Publication Date
JP2010502207A JP2010502207A (ja) 2010-01-28
JP2010502207A5 true JP2010502207A5 (enExample) 2012-09-27
JP5161882B2 JP5161882B2 (ja) 2013-03-13

Family

ID=39027173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009527144A Active JP5161882B2 (ja) 2006-09-07 2007-09-06 インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用
JP2012179593A Active JP5701827B2 (ja) 2006-09-07 2012-08-13 インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012179593A Active JP5701827B2 (ja) 2006-09-07 2012-08-13 インフルエンザウイルスh5n1を中和しうるヒト結合性分子およびその使用

Country Status (15)

Country Link
US (5) US8192927B2 (enExample)
EP (2) EP2450377A1 (enExample)
JP (2) JP5161882B2 (enExample)
KR (1) KR101485197B1 (enExample)
AU (1) AU2007293662B2 (enExample)
CA (1) CA2663388C (enExample)
EA (1) EA017203B1 (enExample)
HR (1) HRP20130163T1 (enExample)
IL (2) IL197390A (enExample)
MX (1) MX2009002174A (enExample)
MY (1) MY170607A (enExample)
NO (1) NO20091321L (enExample)
PL (1) PL2059532T3 (enExample)
WO (1) WO2008028946A2 (enExample)
ZA (1) ZA200901171B (enExample)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
NZ580607A (en) * 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CA2579523C (en) * 2004-10-12 2016-04-12 Crucell Holland B.V. Atad3a-binding molecules for treatment, detection and prevention of cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN102046654A (zh) * 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
EP2132312B1 (en) 2007-03-27 2016-01-27 Sea Lane Biotechnologies,llc. Constructs and libraries comprising antibody surrogate light chain sequences
EP2036045A1 (en) * 2007-07-11 2009-03-18 Cairos technologies AG Video tracking method and appartus arrangement for performing the method
AU2008297594B2 (en) 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) * 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスh5亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
MX2010006148A (es) 2007-12-06 2011-02-23 Dana Farber Cancer Inst Inc Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
WO2009121004A2 (en) * 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
ES2662519T3 (es) * 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
EP2848630A1 (en) 2008-10-22 2015-03-18 Institute for Research in Biomedicine Methods for producing antibodies from plasma cells
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
CN102292350A (zh) 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
WO2010130636A1 (en) * 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CN102482345A (zh) * 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
WO2011019932A2 (en) * 2009-08-14 2011-02-17 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2011044570A2 (en) * 2009-10-09 2011-04-14 Emory University Recombinant antibodies against h1n1 influenza
ES2802623T3 (es) * 2010-01-27 2021-01-20 Massachusetts Inst Technology Agentes polipeptídicos técnicamente diseñados para la neutralización dirigida de amplio espectro de la gripe
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9573991B2 (en) * 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN102241768B (zh) * 2010-05-14 2013-12-25 中国科学院上海生命科学研究院 一种抗甲型h1n1流感病毒血凝素蛋白的抗体
JP6050747B2 (ja) * 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US8900590B2 (en) * 2010-08-12 2014-12-02 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
CA2811103C (en) 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
US9469685B2 (en) * 2011-01-10 2016-10-18 Emory University Antibodies directed against influenza
CA2827301A1 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
US9133272B2 (en) * 2011-03-01 2015-09-15 Amgen Inc. Bispecific binding agents
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
JP6113155B2 (ja) 2011-06-20 2017-04-12 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 計算で最適化した広い反応性を示すh1n1インフルエンザの抗原
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
EP2736928B1 (en) 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3
WO2013033319A2 (en) * 2011-08-30 2013-03-07 The Board Of Trustees Of The Leland Stanford Junior University A cluster of neutralizing antibodies to hepatitis c virus
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドModernaTX,Inc. 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
EP2768858B1 (en) 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
MY170927A (en) * 2011-11-28 2019-09-19 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
JP6325451B2 (ja) * 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー A型インフルエンザに特異的な抗体
CN104302321A (zh) 2011-12-05 2015-01-21 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
WO2013089496A1 (ko) * 2011-12-15 2013-06-20 (주)에이프로젠 H1n1-감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
EP2793940B1 (en) 2011-12-22 2018-11-14 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9234008B2 (en) 2012-02-07 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
MY180109A (en) 2012-02-13 2020-11-23 Univ Pittsburgh Commonwealth Sys Higher Education Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
KR102050615B1 (ko) 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
EP2831094B1 (en) 2012-03-30 2018-06-13 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2712626A1 (en) 2012-09-28 2014-04-02 Fabentech Passive immunisation against influenza, in particular H5N1
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
JP2016505538A (ja) 2012-11-27 2016-02-25 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション H1n1インフルエンザに対する計算で最適化した広い反応性を示す抗原
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
US9624272B2 (en) 2013-03-14 2017-04-18 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
WO2014159960A1 (en) * 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105209071A (zh) 2013-03-14 2015-12-30 抗非特公司 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2982691B1 (en) 2013-04-02 2020-05-06 Xiamen University Broad spectrum monoclonal antibody identifying ha1 structural domain of influenza virus hemagglutinin proteins
EP3004142B1 (en) 2013-05-30 2020-09-30 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
EP3037819A4 (en) * 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus
JPWO2015025900A1 (ja) 2013-08-23 2017-03-02 学校法人藤田学園 抗インフルエンザウイルス中和抗体
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン,エルエルシー 抗a型インフルエンザ抗体の中和及びその使用
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3070167A4 (en) * 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
KR102344390B1 (ko) 2014-02-04 2021-12-28 콘트라펙트 코포레이션 수동 인플루엔자 면역화에 유용한 항체, 및 이의 사용을 위한 조성물, 조합 및 방법
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
RU2021109685A (ru) 2014-04-23 2021-04-13 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
CN106661091B (zh) 2014-07-10 2020-10-30 扬森疫苗与预防公司 流行性感冒病毒疫苗及其用途
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
PH12017501216B1 (en) 2015-02-05 2023-05-24 Janssen Vaccines And Prevention B V Binding molecules directed against influenza hemagglutinin and uses thereof
WO2016124682A1 (en) 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
MX386783B (es) 2015-05-11 2025-03-19 Janssen Vaccines & Prevention Bv Compuestos peptidomiméticos que neutralizan el virus influenza.
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
EP3419663A1 (en) 2016-02-24 2019-01-02 Visterra, Inc. Formulations of antibody molecules to influenza virus
US10703803B2 (en) 2016-03-01 2020-07-07 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza B neuraminidase
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
KR101835009B1 (ko) 2016-08-19 2018-03-07 주식회사 하이딥 터치 입력 장치
CA3040893A1 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US11479600B2 (en) 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018078008A1 (en) 2016-10-27 2018-05-03 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing compounds
EP3574008B1 (en) 2017-01-27 2023-11-08 National Research Council of Canada Hemagglutinin-specific antibodies and uses thereof
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
AU2018216954B2 (en) 2017-02-02 2022-04-14 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
KR102119783B1 (ko) * 2017-08-14 2020-06-08 사회복지법인 삼성생명공익재단 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
RS63526B1 (sr) 2018-01-23 2022-09-30 Janssen Vaccines & Prevention Bv Vakcine za virus gripa i njihove upotrebe
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN111057718A (zh) * 2018-10-17 2020-04-24 南京大学 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法
KR102113302B1 (ko) * 2018-12-24 2020-05-20 원광대학교산학협력단 상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
MX2022002766A (es) 2019-09-05 2022-04-06 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la gripe y usos de las mismas.
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN111440228B (zh) * 2020-03-09 2021-08-24 扬州大学 多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US20210325367A1 (en) * 2020-04-20 2021-10-21 Satish Mahna Controlled Exposure to Pathogens for Generating Immunity
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
WO2022166767A1 (zh) 2021-02-04 2022-08-11 四川海思科制药有限公司 Ha抑制剂化合物的盐及晶型
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
TW202309075A (zh) * 2021-04-30 2023-03-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
EP4619413A2 (en) 2022-11-14 2025-09-24 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾b型流感血球凝集素多肽及核酸及其用途
WO2025090499A1 (en) * 2023-10-24 2025-05-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monoclonal antibodies that bind an antigen of epithelial ovarian cancer and their use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2026027730A1 (en) 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
WO2026052773A1 (en) 2024-09-06 2026-03-12 Sanofi Modified influenza a hemagglutinin polypeptides and nucleic acids and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) * 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4625015A (en) 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JP3584990B2 (ja) * 1994-05-09 2004-11-04 タカラバイオ株式会社 抗ヒトインフルエンザウイルス抗体
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DK0934526T3 (da) 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US6440736B1 (en) 1998-10-16 2002-08-27 U-Bisys B.V. Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
US20030161813A1 (en) 1998-04-30 2003-08-28 Ton Logtenberg Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
ES2237420T5 (es) 1999-04-15 2010-03-03 Crucell Holland B.V. Produccion de proteina recombinante en una celula humana.
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
WO2002103012A1 (en) 2001-06-15 2002-12-27 Crucell Holland B.V. Chimaeric phages
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages
EP2270049A3 (en) * 2002-04-12 2011-03-09 Medimmune, Inc. Recombinant anti-interleukin-9-antibody
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
SG128680A1 (en) 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ATE536376T1 (de) 2003-12-23 2011-12-15 Crucell Holland Bv Humanes bindungsmolekül gegen cd1a
AU2004319642A1 (en) 2004-05-17 2005-11-24 Crucell Holland B.V. Methods for diagnosis of acute myeloid leukemia
NZ580607A (en) 2004-05-27 2011-05-27 Crucell Holland Bv Binding molecules capable of neutralizing rabies virus and uses thereof
CA2579523C (en) 2004-10-12 2016-04-12 Crucell Holland B.V. Atad3a-binding molecules for treatment, detection and prevention of cancer
NZ553701A (en) 2004-11-11 2009-12-24 Crucell Holland Bv Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
JP4580338B2 (ja) 2004-12-23 2010-11-10 エーエスエムエル ネザーランズ ビー.ブイ. リソグラフィ装置、エキシマ・レーザ、およびデバイス製造方法
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
JP4758148B2 (ja) * 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
EP1893645A1 (en) 2005-06-23 2008-03-05 Crucell Holland B.V. Optimization of west nile virus antibodies
KR101274790B1 (ko) 2005-07-22 2013-06-13 크루셀 홀란드 비.브이. 코로나바이러스 생산용 세포주
AU2006290736B2 (en) 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
WO2007141278A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US8802089B2 (en) 2008-01-03 2014-08-12 Genmab A/S Monoclonal antibodies against CD32B
US8148797B2 (en) 2008-06-26 2012-04-03 Taiwan Semiconductor Manufacturing Co., Ltd. Chip pad resistant to antenna effect and method
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
DK2838917T3 (da) 2012-04-20 2019-08-26 Merus Nv Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler

Similar Documents

Publication Publication Date Title
JP2010502207A5 (enExample)
JP2011528901A5 (enExample)
JP2008508859A5 (enExample)
JP2010521147A5 (enExample)
JP2013502204A5 (enExample)
CN103209994B (zh) 可用于被动流感免疫的抗体
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2012526542A5 (enExample)
HRP20130163T1 (hr) Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
JP2011521662A5 (enExample)
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
RU2668802C2 (ru) Антитела, используемые для пассивной вакцинации против гриппа
JP2013531993A5 (enExample)
JP2007097598A5 (enExample)
JP2016524463A5 (enExample)
JP2018524001A5 (enExample)
JP2010515717A5 (enExample)
JP2011528902A5 (enExample)
JP2015143226A5 (enExample)
JP2009225799A5 (enExample)
HRP20190714T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
JP2011524161A5 (enExample)
JP2018033454A5 (enExample)
CN106243218B (zh) 抗Flu B的广谱单克隆抗体及其用途
JP2016503413A5 (enExample)